Latest news

• Merck gets first approval for MET inhibitor tepotinib in Japan

  Merck’s closest rival in the MET-positive lung cancer race is Novartis, whose capmatinib started a priority review in the US last month based on the results of the phase ... That showed an overall response rate with capmatinib of 68% with the drug

• Novartis pulls ahead of Merck in MET-positive lung cancer race

  FDA starts priority review of Swiss pharma's MET inhibitor. Novartis’ MET inhibitor capmatinib could be approved for marketing in the US within six months for a rare form of ... Novartis’ chief medical officer John Tsai said that capmatinib “may be

• Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

  Novartis revealed the phase 2 results from its GEOMETRY mono-1 trial of capmatinib  earlier this year. ... Novartis anticipates a regulatory filing for capmatinib in the US by the end of 2019.

• Rival Novartis, Merck drugs square up on rare lung cancer at ASCO

  Novartis’ capmatinib and Merck’s tepotinib both target the MET-signalling pathway, which is mutated in 3% to 5% of NSCLC cases and tends to cause aggressive tumours with a poor ... The FDA has awarded capmatinib orphan and breakthrough designations